-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Travere Therapeutics, Raises Price Target to $75

Benzinga·08/05/2026 19:45:41
Listen to the news
TD Cowen analyst Tyler Van Buren maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $60 to $75.